In a new head-to-head trial, drugmaker Eli Lilly said Wednesday that patients using its obesity medication Zepbound lost significantly more weight than those who were given competitor Novo Nordisk’s Wegovy.
Eli Lilly said that users of Zepbound, which contains the antidiabetic medication tirzepatide, shed 47 percent more pounds compared to those who were given the other semaglutide drug.